Kraig Biocraft Laboratories Announces Breakthrough in Creation of New Recombinant Spider Silks

Rhea-AI Summary

Kraig Labs has filed a provisional patent for a groundbreaking gene-editing system that enhances the production of recombinant spider silk. This new knock-out/knock-in multiplex system significantly reduces process complexity by over 60%, potentially leading to higher yields. The research team is currently monitoring first-generation transgenics, with results expected in 30 days. Kraig Labs aims to apply this technology beyond silk, with implications for boutique protein production. COO Jon Rice highlighted the innovative team's achievements in unlocking cost-effective, commercial-scale production.

Positive

• Provisional patent filed for an advanced gene-editing system.
• Over 60% reduction in process complexity for creating transgenics.
• Potential for significantly higher yields in recombinant spider silk production.
• Application of new system extends to boutique protein production.

Negative

• None.

Kraig Labs files provisional patent for next-generation gene-editing system

ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that its research team has surpassed a crucial milestone in the creation and production of new recombinant spider silks and other key target proteins. The Company is now raising several batches of first-generation transgenics utilizing this new and more efficient process.

These transgenics represent the first implementation of this new knock-out/knock-in multiplex system for silkworms developed by Kraig Labs’ research team. The new approach results in a greater than 60% reduction in process complexity when creating new transgenics and should result in significantly higher yields. Pairing multiplex targeting with co-expression of trans-proteins, this new system should allow the Company to achieve homozygous, germline stable, new transgenics in a fraction of the time.  

Kraig Labs’ research team will monitor these first-generation transgenics over the next 30 days to verify improvements over existing systems. The Company’s research team has already prepared and filed a potential provisional patent to protect this new novel technology.

“Today’s announcement is just the latest in a string of incredible breakthroughs from our research lab. Our team continues to defy conventional wisdom, finding almost unimaginable solutions and unlocking the potential for cost-effective, commercial-scale spider silk production,” said COO Jon Rice. “This breakthrough is the direct result of our exceptionally creative research team. Through an intentional process of seeking out diverse backgrounds and experiences for all positions throughout the organization, we have built a truly extraordinary team.”

While now focused on improving the production of recombinant spider silk, this new gene system is directly applicable to the Company’s accelerating work in non-fibrous and boutique protein production.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

FAQ

What is the significance of Kraig Labs' new gene-editing system?

Kraig Labs' new gene-editing system increases efficiency in producing recombinant spider silk and may lead to higher yields due to reduced process complexity.

How does the new gene-editing system benefit Kraig Labs?

The system allows for quicker development of stable transgenics, enhancing production capabilities for both spider silk and other proteins.

What does the provisional patent filed by Kraig Labs cover?

The provisional patent covers a next-generation gene-editing system that incorporates knock-out/knock-in multiplex technology for silkworms.

When will Kraig Labs know if their new transgenics are successful?

The research team will monitor the first-generation transgenics over the next 30 days to assess the system's effectiveness.